share_log

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K:HeartSciences提供最新业务并报告2025财年第一季度财务业绩
美股SEC公告 ·  2024/09/13 04:20

Moomoo AI 已提取核心信息

HeartSciences reported Q1 FY2025 results with $4.3M cash and $5.9M shareholder equity. The company secured additional $1.9M through non-dilutive financing and extended a $500,000 loan note to September 2025. Their MyoVista Insights AI-ECG cloud platform is on track for completion by end-2024, with FDA validation studies planned for their first cloud-based algorithm targeting low ejection fraction detection.The company plans FDA 510(k) submission for MyoVista wavECG device in Q1 2025, with hardware and software issues resolved and age-adjusted algorithm nearing completion. The Innovation Value Institute's analysis demonstrated MyoVista's potential to improve cardiovascular pathway efficiency, leading to the company's selection for demonstration at the UN General Assembly Digital Health Symposium.HeartSciences continues expanding its IP portfolio with new patents for deep learning-based ventricular dysfunction detection and MyoVista Wavelet Technology. The company is positioning itself in the projected $25B AI-ECG market through both cloud and device-based solutions, focusing on early heart disease detection.
HeartSciences reported Q1 FY2025 results with $4.3M cash and $5.9M shareholder equity. The company secured additional $1.9M through non-dilutive financing and extended a $500,000 loan note to September 2025. Their MyoVista Insights AI-ECG cloud platform is on track for completion by end-2024, with FDA validation studies planned for their first cloud-based algorithm targeting low ejection fraction detection.The company plans FDA 510(k) submission for MyoVista wavECG device in Q1 2025, with hardware and software issues resolved and age-adjusted algorithm nearing completion. The Innovation Value Institute's analysis demonstrated MyoVista's potential to improve cardiovascular pathway efficiency, leading to the company's selection for demonstration at the UN General Assembly Digital Health Symposium.HeartSciences continues expanding its IP portfolio with new patents for deep learning-based ventricular dysfunction detection and MyoVista Wavelet Technology. The company is positioning itself in the projected $25B AI-ECG market through both cloud and device-based solutions, focusing on early heart disease detection.
HeartSciences公布了2025财年第一季度的财务报告,拥有430万美元现金和590万美元的股东权益。公司通过非稀释性融资获得了190万美元,并将50万美元的贷款票据延长至2025年9月。他们的MyoVista Insights人工智能-心电图云平台预计将在2024年底按期完成,并计划对其第一个云基础算法进行FDA验证研究,目标是检测低射血分数。公司计划在2025年第一季度提交MyoVista wavECG设备的FDA 510(k)申请,硬件和软件问题已解决,并且年龄调整算法即将完成。创新价值研究所的分析显示MyoVista在改善心血管路径效率方面的潜力,从而使公司被选中在联合国大会的...展开全部
HeartSciences公布了2025财年第一季度的财务报告,拥有430万美元现金和590万美元的股东权益。公司通过非稀释性融资获得了190万美元,并将50万美元的贷款票据延长至2025年9月。他们的MyoVista Insights人工智能-心电图云平台预计将在2024年底按期完成,并计划对其第一个云基础算法进行FDA验证研究,目标是检测低射血分数。公司计划在2025年第一季度提交MyoVista wavECG设备的FDA 510(k)申请,硬件和软件问题已解决,并且年龄调整算法即将完成。创新价值研究所的分析显示MyoVista在改善心血管路径效率方面的潜力,从而使公司被选中在联合国大会的互联网医疗研讨会上进行展示。HeartSciences继续扩展其知识产权组合,获得了基于深度学习的心室功能障碍检测和MyoVista小波技术的新专利。公司致力于通过云和设备设计解决方案在预计250亿美元的人工智能-心电图市场中占据一席之地,专注于早期心脏疾病检测。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息